Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DRT102-sp is an engineered bone morphogenetic protein (BMP) biobetter in the design and concept stages of development by OSR Holdings and its subsidiary, Darnatein. Utilizing the proprietary DA-BMP (Darnatein-BMP) platform, the asset is designed to enhance BMP pathway activity to support bone and spinal regeneration. The program is currently being explored for orthopedic and dental applications, including lumbar stenosis, disc herniation, spinal fusion, dental augmentation, and non-union bone fractures. It represents an earlier-stage iteration or specialized version of the core DRT-102 program, focusing on targeted bone growth and structural repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DRT102-sp.